- Home
- MXL vs RCUS Comparison
MXL vs RCUS Comparison
Compare MXL & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MXL
- RCUS
- Stock Information
- Founded
- MXL 2003
- RCUS 2015
- Country
- MXL United States
- RCUS United States
- Employees
- MXL N/A
- RCUS N/A
- Industry
- MXL Semiconductors
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- MXL Technology
- RCUS Health Care
- Exchange
- MXL Nasdaq
- RCUS Nasdaq
- Market Cap
- MXL 1.4B
- RCUS 1.2B
- IPO Year
- MXL 2010
- RCUS 2018
- Fundamental
- Price
- MXL $15.96
- RCUS $13.18
- Analyst Decision
- MXL Buy
- RCUS Buy
- Analyst Count
- MXL 8
- RCUS 8
- Target Price
- MXL $20.93
- RCUS $20.71
- AVG Volume (30 Days)
- MXL 1.1M
- RCUS 851.9K
- Earning Date
- MXL 10-22-2025
- RCUS 11-05-2025
- Dividend Yield
- MXL N/A
- RCUS N/A
- EPS Growth
- MXL N/A
- RCUS N/A
- EPS
- MXL N/A
- RCUS N/A
- Revenue
- MXL $378,015,000.00
- RCUS $262,000,000.00
- Revenue This Year
- MXL $28.85
- RCUS N/A
- Revenue Next Year
- MXL $17.69
- RCUS N/A
- P/E Ratio
- MXL N/A
- RCUS N/A
- Revenue Growth
- MXL N/A
- RCUS 6.07
- 52 Week Low
- MXL $8.35
- RCUS $6.50
- 52 Week High
- MXL $25.73
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- MXL 49.89
- RCUS 73.39
- Support Level
- MXL $15.41
- RCUS $12.15
- Resistance Level
- MXL $17.19
- RCUS $12.99
- Average True Range (ATR)
- MXL 0.70
- RCUS 0.53
- MACD
- MXL -0.05
- RCUS 0.05
- Stochastic Oscillator
- MXL 34.83
- RCUS 93.76
About MXL MaxLinear Inc.
MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.